<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439943</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8912</org_study_id>
    <nct_id>NCT03439943</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease</brief_title>
  <acronym>LixiPark</acronym>
  <official_title>Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cure Parkinson</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Réseau NS-Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUCLID Clinical Trial Platform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus&#xD;
      placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the&#xD;
      progression of motor disability in patients with early PD in order to assess its potential&#xD;
      &quot;disease-modifying&quot; effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a French, multicenter parallel groups, 2-arm, randomized,&#xD;
      placebo-controlled, double-blind, proof-of-concept (POC) phase II trial evaluating the effect&#xD;
      of lixisenatide, in patients with early PD.&#xD;
&#xD;
      The treatment period will be followed by a wash-out period of 2 months.&#xD;
&#xD;
      JUSTIFICATION/CONTEXT Parkinson's disease (PD) is a common neurodegenerative disease.&#xD;
      Currently available symptomatic treatments allow improving motor and to a lesser extent&#xD;
      non-motor function in PD patients.&#xD;
&#xD;
      None of these treatments can slow down the underlining disease process and the relentless&#xD;
      progression of motor and non-motor disability.&#xD;
&#xD;
      Several mechanisms including the aggregation of misfolded alphasynuclein, mitochondrial&#xD;
      dysfunction, oxidative stress and neuroinflammation have been related to the pathogenesis of&#xD;
      PD. Recent evidence further suggests the implication of cerebral insulin resistance in the&#xD;
      neurodegenerative process, while glucagon-like peptide 1 receptor (GLP1-R) agonists that are&#xD;
      approved for the treatment of type 2 diabetes have neuroprotective properties in animal&#xD;
      models of PD (Aviles-Olmos et al., 2013a). Moreover, the results of a recent clinical pilot&#xD;
      trial suggest that treatment with the GLP-1R agonist exenatide for 12 months improves motor&#xD;
      function in patients with moderate PD . GLP1-R are widely expressed in the central nervous&#xD;
      system and GLP1-R agonists such as liraglutide, lixisenatide and exenatide have measurable&#xD;
      brain concentrations, which makes them suitable for treating brain disorders.&#xD;
&#xD;
      Lixisenatide is a well-tolerated GLP-1R agonist that can be administered once-daily&#xD;
      (subcutaneous injection). It has demonstrated positive effects on learning and memory through&#xD;
      an increase of hippocampal neurogenesis in preclinical models of obesity/diabetes.&#xD;
      Furthermore, lixisenatide increases neurogenesis and decreases microglial activation in&#xD;
      rodent models of Alzheimer's disease (APPswe/PS1ΔE9 mice and Aβ25-35 rats) (. At the same&#xD;
      dose, lixisenatide showed higher effectiveness at activating brain GLP-1R than liraglutide&#xD;
      and exenatide, and showed more effective neuroprotection in a variety of in-vitro models of&#xD;
      neurodegeneration (WO2013/030409A1).&#xD;
&#xD;
      Thus, this randomized, double-blind, clinical trial now aim to evaluate the effects of&#xD;
      lixisenatide, versus placebo, on both motor and non-motor PD symptoms in patients at an early&#xD;
      stage of PD.&#xD;
&#xD;
      This study will involve centers of the French national Parkinson's disease and movement&#xD;
      disorders research network (Ns-Park network).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to end-point (M12) in the MDS-UPDRS III motor ( Movement Disorder Society-Unified Parkinson's disease rating scale)</measure>
    <time_frame>12 month</time_frame>
    <description>The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential &quot;disease-modifying&quot; effect.&#xD;
The primary endpoint of this study is the change from baseline to end-point (M12) in the MDS-UPDRS III motor examination score, evaluated in the best ON condition in patients with early Parkinson's Disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: once daily subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>injection drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with PD according to UKPDSBB criteria (male or female).&#xD;
&#xD;
          -  Patient with a Hoehn and Yahr Stage &lt;3 in the ON condition.&#xD;
&#xD;
          -  Patients aged from 40 to 75 years old.&#xD;
&#xD;
          -  Early-stage PD patients: diagnosis of PD for less than 3 years, without dyskinesia and&#xD;
             motor fluctuations.&#xD;
&#xD;
          -  Patients treated with an &quot;optimized&quot; stable dopaminergic medication regimen (dopamine&#xD;
             agonist and/or L-dopa and/or MAOB inhibitor) for at least 1 month before baseline.&#xD;
&#xD;
          -  Patients expected to remain on stable doses of antiparkinsonian medications for at&#xD;
             least the first 6 months of the study and preferably for the 12 months of follow-up.&#xD;
&#xD;
          -  Patients (or caregiver) able to self-administer lixisenatide injection.&#xD;
&#xD;
          -  Patients with health insurance.&#xD;
&#xD;
          -  Patients who signed the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from other parkinsonian syndromes other than PD.&#xD;
&#xD;
          -  Patients expected not to be able to remain on stable doses of symptomatic&#xD;
             antiparkinsonian medications for at least 6-month.&#xD;
&#xD;
          -  Patients with a Body Mass Index &lt; 18.5&#xD;
&#xD;
          -  Patients suffering from type 1 or type 2 diabetes.&#xD;
&#xD;
          -  Malnutrition as assessed clinically by the investigator or any sub-investigator and by&#xD;
             Mini Nutritional Assessment Short Form (MNA-SF) score &lt;12 (the judgement of the&#xD;
             investigator prevails over questionnaire scores).&#xD;
&#xD;
          -  Weight change of more than 5 kg in body weight during the last 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Known history of drug or alcohol abuse within 6 months prior to the time of screening.&#xD;
&#xD;
          -  Patients with hyperthyroidism or uncontrolled hypothyroidism. Note: Patients diagnosed&#xD;
             with hypothyroidism need to be on a stable thyroid replacement therapy for at least 6&#xD;
             weeks.&#xD;
&#xD;
          -  Patients with severe depression according to DSM criteria.&#xD;
&#xD;
          -  Patients with cognitive impairment (MoCA score &lt;26).&#xD;
&#xD;
          -  Severe gastrointestinal disease (e.g. gastroparesis).&#xD;
&#xD;
          -  Patients previously exposed to a GLP-1 agonist.&#xD;
&#xD;
          -  Patients with severely impaired renal function (estimated creatinine clearance&#xD;
             &lt;30ml/min).&#xD;
&#xD;
          -  Patients with a medical history of active liver disease (other than non-alcoholic&#xD;
             hepatic steatosis), including chronic active hepatitis B or C (assessed by medical&#xD;
             history), primary biliary cirrhosis, or ongoing symptomatic gallbladder disease.&#xD;
&#xD;
          -  Patients with any clinically significant ECG abnormality.&#xD;
&#xD;
          -  Laboratory findings at the time of screening:&#xD;
&#xD;
        Amylase and/or lipase: &gt;3 times the upper limit of the normal (ULN) laboratory range ALT or&#xD;
        AST: &gt;3 times ULN Total bilirubin: &gt;1.5 times ULN (except in case of Gilbert's syndrome)&#xD;
        Calcitonin: &gt;20 pg/mL (5.9 pmol/L) Hemoglobin: &lt;11 g/dL (male/female) and/or neutrophils&#xD;
        &lt;1,500/mm3 and/or platelets &lt;100,000/mm3 Triglyceride (TG): &gt;600 mg/dL (6.78 mmol/L).&#xD;
        History of unexplained pancreatitis, chronic pancreatitis or pancreatectomy.&#xD;
&#xD;
          -  Personal or immediate family history of medullary thyroid cancer or genetic conditions&#xD;
             that predispose to medullary thyroid cancer (e.g. multiple endocrine neoplasia&#xD;
             syndromes).&#xD;
&#xD;
          -  Hyperlipidemia.&#xD;
&#xD;
          -  Females who are pregnant, breast feeding or of child bearing age without effective&#xD;
             contraception.&#xD;
&#xD;
          -  Patients treated per os in the evening by drugs requiring a rapid action (at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
          -  Participants who lack the capacity to give informed consent.&#xD;
&#xD;
          -  Any medical or psychiatric condition which may compromise participation in the study&#xD;
             or the safety, at the discretion of the investigator.&#xD;
&#xD;
          -  Known abnormality on CT or MRI brain imaging that is considered likely to compromise&#xD;
             compliance with any aspect of the trial.&#xD;
&#xD;
          -  Prior intra-cerebral surgical intervention for PD.&#xD;
&#xD;
          -  Participant under legal guardianship or incapacitation.&#xD;
&#xD;
          -  Patients who are participating or have participated in another interventional clinical&#xD;
             trial within 30 days prior to baseline.&#xD;
&#xD;
          -  Previous enrolment in the present trial.&#xD;
&#xD;
          -  Allergic reaction to the active substance or to any of the excipients of lixisenatide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier. RASCOL, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creteil- Henri Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

